Get the Stockscreener App
1.88
5.53%
-0.11
Pre-market:
1.76
-0.12
-6.38%
Bioaffinity Technologies Inc stock is traded at $1.88, with a volume of 96,028.
It is down -5.53% in the last 24 hours and down -35.84% over the past month.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
See More
Previous Close:
$1.99
Open:
$1.92
24h Volume:
96,028
Relative Volume:
0.01
Market Cap:
$8.53M
Revenue:
$6.16M
Net Income/Loss:
$-14.91M
P/E Ratio:
-0.1762
EPS:
-10.6693
Net Cash Flow:
$-9.39M
1W Performance:
-7.39%
1M Performance:
-35.84%
6M Performance:
+2.17%
1Y Performance:
-69.52%
1-Day Range:
$1.88
$1.99
1-Week Range:
$1.86
$2.1797
52-Week Range:
$0.693
$15.00
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.88 | 9.02M | 6.16M | -14.91M | -9.39M | -10.67 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
bioAffinity Technologies Inc (BIAF) Stock Price, Quote, News & History - Benzinga
bioAffinity Technologies, Inc.Warrant (NQ: BIAFW - FinancialContent
bioAffinity (BIAF) registers 497,483 resale shares, includes 365,603 warrants - Stock Titan
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - Yahoo Finance
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan
bioAffinity reports 300% jump in lung test sales in April - Investing.com UK
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Ye - PharmiWeb.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - 01net
bioAffinity Technologies Reports Record 300% Growth in CyPath® Lung Diagnostic Test Sales in April 2026 - Minichart
bioAffinity CyPath Lung Test Sales Surge Sharply - TipRanks
TradingKey - TradingKey
bioAffinity reports 300% jump in lung test sales in April By Investing.com - Investing.com Australia
bioAffinity Reports Record Monthly CyPath Lung Unit Sales, April Up Nearly 300% - TradingView
Record CyPath Lung growth at bioAffinity (NASDAQ: BIAF) with April unit sales up nearly 300% - Stock Titan
bioAffinity Technologies, Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
bioAffinity Technologies reports net loss of USD 3.6M in Q1 2026 - Medical Buyer
bioAffinity Technologies, Inc. 1Q 2026: Revenue $1.35M, EPS $(0.81) — 10-Q Summary - TradingView
BioAffinity Technologies : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Q1 2026 loss deepens at bioAffinity Technologies (NASDAQ: BIAF) - Stock Titan
bioAffinity Technologies Releases Q1 2026 Financial Results - AlphaStreet
BIAF | bioAffinity Technologies, Inc. Common Insider Trading - Quiver Quantitative
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - BioSpace
Bioaffinity Technologies IncQ1 2026 net loss $3.6 million or $0.81 per share - marketscreener.com
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CyPath Lung growth stands out in bioAffinity (NASDAQ: BIAF) Q1 2026 results - Stock Titan
Press Release: BioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath(R) Lung - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
bioAffinity Shareholders Approve Equity Plan and Capital Measures - TipRanks
Investors in bioAffinity (NASDAQ: BIAF) register 497,483 shares for resale - Stock Titan
8-K: Current report - Moomoo
bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split - Stock Titan
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - BioSpace
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - MSN
BIAF stock gains as CyPath sales surge 146% in Q1 - MSN
FinancialContentbioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - FinancialContent
bioAffinity Technologies prices $4.8 million public offering; shares down over 30% - MSN
bioAffinity Technologies Working With U.S. Army on CyPath Lung Study - Medical Product Outsourcing
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):